Document is current
Any future updates will be listed below
-
Authors
Abraham, Preethy E.
Johnson, Douglas B. https://orcid.org/0000-0002-6390-773X
- License Information
-
More Information
Article History
Received: 9 June 2025
Accepted: 3 September 2025
First Online: 30 September 2025
Declarations
:
: Preethy Abraham and Douglas Johnson wrote the initial version, provided edits, and approved the finalized version.
: D.B.J. has served on advisory boards or as a consultant for AstraZeneca, BMS, Daiichi Sankyo, The Jackson Laboratory, Merck, Mosaic ImmunoEngineering, Novartis, Pfizer, and Teiko; has received research funding from BMS and Incyte; and has patents pending for use of MHC-II as a biomarker for immune-checkpoint-inhibitor response and abatacept as treatment for immune-related adverse events. P.E.A. declares that she has no conflicts of interest that might be relevant to the contents of this manuscript.
: Not applicable.
: Not applicable.
: Not applicable.
: No datasets were generated or analyzed during the current study.
: Not applicable.
